Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss drugs towards the end of the year. Novo saw But Novo said Wednesday it expects slower growth in 2025 compared to the prior year.
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...
One study compared GLP-1RAs against another weight loss drug, bupropion-naltrexone ... As these drugs continue to gain popularity and achieve commercial success, their list of indications ...
Pharmacists must verify a person’s body mass index (BMI) via a video consultation, in person, or through accessing GP or ...
insurers often don't pay for these drugs for weight loss. List prices exceed $1,000 per month and spotty insurance coverage means many consumers struggle to afford the medications, ...
‘Wonder drugs’ like Ozempic, hailed by celebrities and some medics as a cure for an ever-mounting list of conditions ... 30 after taking a drug for weight loss — something it is not licensed ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
But his joy was short-lived: Last April, the North Carolina State Health Plan for teachers and other public employees stopped covering the drug for weight loss. The list price for Wegovy tops ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback